Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.

ABSTRACT:

Aims

Loop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin-angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF treatment.

Methods and results

Sixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7.5 mg oral tolvaptan for 5 days after admission. Both groups also received intravenous carperitide and canrenoate potassium. As results, baseline patient characteristics were similar between the furosemide (n = 30) and the to

SUBMITTER: Jujo K 

PROVIDER: S-EPMC5071712 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature